Capricor Therapeutics (NASDAQ:CAPR) Trading 7.3% Higher After Analyst Upgrade

Capricor Therapeutics Inc (NASDAQ:CAPR)’s stock price rose 7.3% during trading on Thursday after Cantor Fitzgerald raised their price target on the stock from $25.00 to $30.00. Cantor Fitzgerald currently has an overweight rating on the stock. Capricor Therapeutics traded as high as $18.25 and last traded at $18.15. Approximately 216,121 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 1,141,077 shares. The stock had previously closed at $16.91.

Other equities research analysts also recently issued research reports about the stock. Maxim Group raised their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Piper Sandler initiated coverage on shares of Capricor Therapeutics in a research report on Monday, October 21st. They issued an “overweight” rating and a $35.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, October 9th. Finally, Oppenheimer reiterated an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Insider Transactions at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the company’s stock in a transaction dated Friday, September 20th. The stock was acquired at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the purchase, the insider now directly owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This trade represents a 65.21 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 12.00% of the company’s stock.

Institutional Trading of Capricor Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CAPR. BNP Paribas Financial Markets purchased a new stake in Capricor Therapeutics in the 1st quarter worth approximately $40,000. Vanguard Group Inc. grew its stake in Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after acquiring an additional 200,499 shares during the period. Bank of New York Mellon Corp grew its stake in Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after acquiring an additional 9,040 shares during the period. Rhumbline Advisers purchased a new stake in Capricor Therapeutics in the 2nd quarter worth approximately $147,000. Finally, Main Street Financial Solutions LLC grew its stake in Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 7,500 shares during the period. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Trading Up 0.6 %

The company’s 50 day moving average price is $15.21 and its 200-day moving average price is $8.46. The company has a market capitalization of $845.08 million, a PE ratio of -17.56 and a beta of 4.00.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.